Eytan Ruppin, MD, PhD, has been appointed Deputy Director of the Translational Research Institute as well as Director of Integrative Data Sciences in the Division of Surgical Research at Cedars-Sinai Cancer.
Eytan Ruppin, MD, PhD
“We are delighted to welcome Dr. Ruppin to Cedars-Sinai as a prestigious senior scientist enriching our cancer discovery programs,” stated Shlomo Melmed, MB, ChB, Executive Vice President of Medicine and Health Sciences and Dean of the Medical Faculty at Cedars-Sinai.
Most recently, Dr. Ruppin was the founding Chief of the Cancer Data Science Lab at the National Cancer Institute, where he was working to develop new approaches to next-generation precision medicine that combine artificial intelligence and transcriptomics. Dr. Ruppin and other members of the Cancer Data Science Lab have validated the approach in breast cancer, and it is being tested further in other cancer types.
At the Translational Research Institute at Cedars-Sinai—which leverages advanced technologies and interdepartmental, interinstitutional collaborations to pursue high-impact research—Dr. Ruppin will continue these research endeavors in clinical studies of diverse patient populations.
“The Translational Research Institute is committed to establishing Cedars-Sinai as a global leader in translating scientific discoveries into life-changing patient care, and Dr. Ruppin’s work dovetails perfectly with this mission,” said Ze’ev Ronai, PhD, Professor of Surgery and Biomedical Sciences and Director of the Translational Research Institute at Cedars-Sinai Cancer.
Dr. Ruppin’s Professional Experience
Dr. Ruppin received his MD and PhD in Computer Science from Tel Aviv University. In 1995, he was appointed Professor of Computer Science & Medicine at Tel Aviv University and conducted computational multidisciplinary research. In July 2014, he became Professor of Computer Science and Director of the Center for Bioinformatics and Computational Biology at the University of Maryland, and then he transferred to the National Cancer Institute in January 2018.
Dr. Ruppin is a fellow of the International Society for Computational Biology and has served on the editorial boards of EMBO Reports and Molecular Systems Biology. He has also received awards for his work in precision medicine, synthetic lethality, and computational biosciences. He is a member of several scientific advisory boards, including GSK Oncology, Pangea Biomed, Win Consortium, and ProCan Technologies. Additionally, he has co-founded several precision medicine and cancer drug discovery startup companies, including Metabomed, MedAware, and Pangea Biomed.
